
    
      The first part of the study will determine the maximum tolerated dose (MTD), dose-limiting
      toxicities (DLTs), and the recommended Phase 2 (RPII) dose of NC-6300. The second part of the
      study will assess the activity and tolerability of NC-6300 in patients with soft tissue
      sarcoma.
    
  